Skip to main content

Tectonic Therapeutic, Inc.

TECX
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
SEC CIK
0001681087

In the last 90 days, Tectonic Therapeutic, Inc. insiders filed 0 open-market purchases and 3 sales; 122 institutions reported holding it in 13F filings for Q2 2026, worth $479.9M in total; no superinvestor holds it.

Open-market trades, last 90 days

Open-market purchases (P) and sales (S) by Tectonic Therapeutic, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.

Open-market buys
0 filings
Open-market sells
3 filings
1 insider, $9.10K in total
Insiders trading
1
Net value
−$9.10K
Purchases minus sales

Insider roster

Directors, officers and 10% owners who have filed a Form 4 for Tectonic Therapeutic, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.

Insider roster for Tectonic Therapeutic, Inc.
NameTitleLast reported holdingLast filingFilings, past year
Schwabish MarcChief Business Officer45,314Sep 8, 20265
McNamara PeterChief Scientific Officer55,285Sep 8, 20269
Lochner DanielChief Financial Officer58,544Sep 8, 20266
Ruddy Marcella K.Chief Medical Officer67,682Sep 8, 20267
Reicin AliseChief Executive Officer310,623Sep 8, 20267
Springer Timothy ADirector, 10% Owner1,503,358IndirectJun 10, 20261
Donenberg Phillip B.Director–Jun 10, 20261
Tipirneni Praveen P.Director3,037Jun 10, 20261
Vitorovic StefanDirector27,774IndirectJun 10, 20261
Chutter Jessica CarolineDirector–Jun 10, 20261
Nader FrancoisDirector–Apr 3, 20261
McGuire TerranceDirector573,062IndirectJun 11, 20250
Leonard Braden MichaelOther: Former 10% owner of AVROBIO33,333Jun 25, 20240
Cortis ChristianChief Operating Officer126,368Jun 24, 20240
Avruch StevenChief Legal Officer22,022Feb 5, 20240
Ostrowski ErikInterim CEO, President and CFO29,285Feb 5, 20240
Ridha EssraChief Medical Officer15,881Feb 5, 20240
Golipour AzadehChief Technology Officer55,872Feb 5, 20240
Clark Ian TDirector–Jun 8, 20230
Booth BruceDirector–Jun 8, 20230
Farfel Gail MDirector–Jun 8, 20230
Vickers Philip J.Director4,800Jun 8, 20230
Jenkins AnnalisaDirector–Jun 8, 20230
Paige ChristopherDirector–Jun 8, 20230
Petersen Deanna MChief Business Officer–Feb 10, 20230
Mackay GeoffreyPresident & CEO188,012Feb 10, 20230

Insider trades

Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Aug 26, 2026 (view filing)4:30 PM ETAug 251 dayMcNamara PeterChief Scientific OfficerSSale−43$36.52−$1.57K−0.1%55.3K after10b5-1
Aug 14, 2026 (view filing)7:25 PM ETAug 122 daysMcNamara PeterChief Scientific OfficerSSale−43$35.00−$1.50K−0.1%55.3K after10b5-1
Jul 1, 2026 (view filing)5:19 PM ETJun 301 dayMcNamara PeterChief Scientific OfficerSSale−172$35.00−$6.02K−0.3%55.3K after10b5-1
May 6, 2026 (view filing)May 42 daysRuddy Marcella K.Chief Medical OfficerSSale−1.06K$30.00−$31.9K−1.5%67.7K after10b5-1
Apr 3, 2026 (view filing)Apr 12 daysRuddy Marcella K.Chief Medical OfficerSSale−1.00K$31.05−$31.1K−1.4%68.7K after10b5-1
Mar 9, 2026 (view filing)Mar 63 daysRuddy Marcella K.Chief Medical OfficerSSale−10.0K$30.00−$300.0K−12.5%69.7K after10b5-1
Mar 9, 2026 (view filing)Mar 63 daysMcNamara PeterChief Scientific OfficerSSale−6.26K$30.17−$188.9K−10.2%55.3K after2 lots10b5-1
Mar 5, 2026 (view filing)Mar 3-42 daysMcNamara PeterChief Scientific OfficerSSale−3.30K$23.53−$77.6K−5.3%58.8K after2 lots10b5-1
Mar 5, 2026 (view filing)Feb 1122 daysReicin AliseChief Executive OfficerPPurchase+2.50K$21.10+$52.8K+2.0%127.0K afterAmended
Feb 11, 2026 (view filing)Feb 101 dayLochner DanielChief Financial OfficerPPurchase+6.00K$21.61+$129.7K+23.0%32.0K after
Apr 11, 2025 (view filing)Apr 9-112 daysSpringer Timothy ADirector, 10% OwnerPPurchase+21.3K$16.20+$344.8K+0.5%4.33M after4 lots
Apr 11, 2025 (view filing)Apr 9-112 daysSpringer Timothy ADirector, 10% OwnerPPurchase+120.6K$16.20+$1.95M+8.7%1.50M after4 lots
Apr 9, 2025 (view filing)Apr 72 daysSpringer Timothy ADirector, 10% OwnerPPurchase+87.5K$17.10+$1.50M+2.1%4.31M after
Apr 9, 2025 (view filing)Apr 72 daysSpringer Timothy ADirector, 10% OwnerPPurchase+412.5K$17.10+$7.05M+42.5%1.38M after
Apr 7, 2025 (view filing)Apr 7Same dayMcGuire TerranceDirectorSSale−500.0K$17.10−$8.55M−46.6%573.1K after
Feb 7, 2025 (view filing)Feb 52 daysSpringer Timothy ADirector, 10% OwnerPPurchase+129.3K$54.14+$7.00M+3.2%4.23M after
Feb 7, 2025 (view filing)Feb 52 daysSpringer Timothy ADirector, 10% OwnerPPurchase+660.0K$50.00+$33.0M+212.8%970.2K after
Feb 7, 2025 (view filing)Feb 52 daysLochner DanielChief Financial OfficerPPurchase+4.62K$54.14+$250.0KNew position4.62K after
Oct 24, 2024 (view filing)Oct 222 daysSpringer Timothy ADirector, 10% OwnerPPurchase+300.0K$33.59+$10.1M+7.9%4.10M after
Sep 26, 2024 (view filing)Sep 26Same daySpringer Timothy ADirector, 10% OwnerPPurchase+50.0K$28.82+$1.44M+1.3%3.80M after4 lots
May 15, 2024 (view filing)May 13-142 daysLeonard Braden Michael10% OwnerPPurchase+766.6K$1.27+$972.8K+19.2%4.77M after3 lots
Jul 8, 2021 (view filing)Jul 71 dayVickers Philip J.DirectorPPurchase+4.80K$8.35+$40.1KNew position4.80K after